Publications by authors named "Marcia Higashi"
Long-Term Safety and Effectiveness of Rituximab Biosimilar RTXM83: A Retrospective Extension Study in Brazilian Patients with Diffuse Large B-Cell Lymphoma.
Oncol Ther
September 2024
Article Synopsis
- RTXM83, a biosimilar to rituximab, has been approved after extensive studies showed it is similar to the original drug; this includes results from a pivotal study called RTXM83-AC-01-11.
- A retrospective study in Brazil analyzed long-term outcomes for patients with diffuse large B cell lymphoma (DLBCL) who received either RTXM83 or the original rituximab alongside other chemotherapy drugs, revealing that both groups showed significant progress in treatment.
- The findings highlighted that RTXM83 had a much higher progression-free survival and overall survival rate compared to the original drug, indicating its effectiveness and safety, although further research is needed to confirm these results in
TERRA (telomeric repeat-containing RNA) is a class of long noncoding RNAs transcribed from subtelomeric and telomeric regions. TERRA binds to the subtelomeric and telomeric DNA-forming R-loops (DNA-RNA hybrids), which are involved in telomere maintenance and telomerase function, but the role of TERRA in human cells is not well characterized. Here, we comprehensively investigated for the first time TERRA expression in primary human hematopoietic cells from an exploratory cohort of patients with acute myeloid leukemia (AML), patients with acute lymphoblastic leukemia (ALL), patients with telomere biology disorder (TBD), and healthy subjects.
View Article and Find Full Text PDFOverall survival of Brazilian acute myeloid leukemia patients according to the European LeukemiaNet prognostic scoring system: a cross-sectional study.
Med Oncol
September 2018
Prognostic stratification in acute myeloid leukemia (AML) relies, mostly, on cytogenetics and molecular features of leukemic blasts. The LeukemiaNet prognostic scoring system has been proposed as a standardized way of evaluating prognosis in AML. We have analysed outcomes in 65 AML cases (median age of 54 years, range 18-82) treated at five hematology centers in Brazil stritified according to the European Leukemia Net (ELN) recommendations for cytogenetic and molecular analysis.
View Article and Find Full Text PDF